Search

Your search keyword '"Lassen, Jens Flensted"' showing total 17 results
Start Over Author "Lassen, Jens Flensted" Journal journal of the american college of cardiology
17 results on '"Lassen, Jens Flensted"'

1. 2-Year Clinical Outcomes After Implantation of Sirolimus-Eluting, Paclitaxel-Eluting, and Bare-Metal Coronary Stents: Results From the WDHR (Western Denmark Heart Registry)

Author

Kaltoft, Anne, Jensen, Lisette Okkels, Maeng, Michael, Tilsted, Hans Henrik, Thayssen, Per, Bøttcher, Morten, Lassen, Jens Flensted, Krusell, Lars Romer, Rasmussen, Klaus, Hansen, Knud Nørregaard, Pedersen, Lars, Johnsen, Søren Paaske, Sørensen, Henrik Toft, and Thuesen, Leif

Published
2009
Full Text
View/download PDF

3. TCT-29 Performance and healing patterns after implantation of a novel sirolimus eluting bioresorbable scaffold. Six-month follow-up by optical coherence tomography in the FANTOM II study

Author

Simonsen, Jo, primary, Holck, Emil, additional, Carrié, Didier, additional, Frey, Norbert, additional, Lutz, Matthias, additional, Weber-Albers, Joachim, additional, Dudek, Dariusz, additional, Chevalier, Bernard, additional, Dijkstra, Jouke, additional, Lassen, Jens Flensted, additional, Anderson, Jeffrey, additional, Christiansen, Evald, additional, Abizaid, Alexandre, additional, and Holm, Niels, additional

Published
2016
Full Text
View/download PDF

4. TCT-451 Two-year outcomes after revascularization with a biodegradable polymer ultra-thin strut sirolimus eluting stent and a biodegradable polymer biolimus-eluting stent. From the SORT OUT VII trial

Author

Jensen, Lisette Okkels, primary, Maeng, Michael, additional, Raungaard, Bent, additional, Hansen, Knud Noerregaard, additional, Kahlert, Johnny, additional, Jensen, Svend Eggert, additional, Bøtker, Hans Erik, additional, Hansen, Henrik, additional, Lassen, Jens Flensted, additional, and Christiansen, Evald, additional

Published
2016
Full Text
View/download PDF

5. TCT-321 Definite and probable stent thrombosis after revascularization with drug-eluting stents with a biodegradable polymer. From the randomized SORT OUT VII Trial

Author

Jensen, Lisette Okkels, primary, Maeng, Michael, additional, Raungaard, Bent, additional, Hansen, Knud Noerregaard, additional, Kahlert, Johnny, additional, Jensen, Svend Eggert, additional, Bøtker, Hans Erik, additional, Hansen, Henrik, additional, Lassen, Jens Flensted, additional, and Christiansen, Evald, additional

Published
2016
Full Text
View/download PDF

6. TCT-318 Ten-year All-cause Mortality after Simple versus Complex Stenting of Coronary Artery Bifurcation Lesions in the Randomized Nordic Bifurcation Study

Author

Steigen, Terje, primary, Holm, Niels, additional, Kumsars, Indulis, additional, Niemela, Matti, additional, James, Stefan, additional, Erglis, Andrejs, additional, Kervinen, Kari, additional, Jensen, Jan Skov, additional, Galloe, Anders Michael, additional, Wiseth, Rune, additional, Gunnes, Paul, additional, Meyerdierks, Oliver, additional, Rotevatn, Svein, additional, Vikman, Saila, additional, Maeng, Michael, additional, Ravkilde, Jan, additional, Ylitalo, Antti, additional, Helqvist, Steffen, additional, Sjogren, Iwar, additional, Jensen, Lisette Okkels, additional, Laine, Mika, additional, Hartikainen, Juha, additional, Airaksinen, Juhani, additional, Lassen, Jens Flensted, additional, Thuesen, Leif, additional, and Christiansen, Evald, additional

Published
2016
Full Text
View/download PDF

7. INTERACTION BETWEEN MORPHINE AND TICAGRELOR IN THE ATLANTIC STUDY

Author

Lapostolle, Frédéric, primary, van ‘t Hof, Arnoud W., additional, Hamm, Christian W., additional, Lassen, Jens Flensted, additional, Stibbe, Olivier, additional, Ecollan, Patrick, additional, Heutz, Wim M.J.M, additional, Licour, Muriel, additional, Tsatsaris, Anne, additional, and Montalescot, Gilles, additional

Published
2016
Full Text
View/download PDF

8. Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents

Author

Jensen, Lisette Okkels, primary, Thayssen, Per, additional, Christiansen, Evald Høj, additional, Maeng, Michael, additional, Ravkilde, Jan, additional, Hansen, Knud Nørregaard, additional, Hansen, Henrik Steen, additional, Krusell, Lars, additional, Kaltoft, Anne, additional, Tilsted, Hans Henrik, additional, Berencsi, Klara, additional, Junker, Anders, additional, and Lassen, Jens Flensted, additional

Published
2016
Full Text
View/download PDF

9. TCT-355 Coronary Stents In Patients With Diabetes Mellitus: The Diabetes And Drug-Eluting Stent (DiabeDES IV) Randomized Angiography Trial

Author

Maeng, Michael, primary, Baranauskas, Arvydas, additional, Thuesen, Leif, additional, Lassen, Jens Flensted, additional, Bøtker, Hans Erik, additional, Krusell, Lars, additional, Ravkilde, Jan, additional, Tilsted, Hans-Henrik, additional, Junker, Anders, additional, Thayssen, Per, additional, and Jensen, Lisette Okkels, additional

Published
2012
Full Text
View/download PDF

10. TCT-347 Clinical Outcome Of Biolimus-Eluting Versus Sirolimus-Eluting Coronary Stent Implantation In Patients With And Without Diabetes Mellitus: A SORT OUT V Substudy

Author

Maeng, Michael, primary, Christiansen, Evald, additional, Tilsted, Hans-Henrik, additional, Ravkilde, Jan, additional, Thayssen, Per, additional, Jensen, Lisette, additional, Madsen, Morten, additional, Krusell, Lars, additional, Bøtker, Hans Erik, additional, Thuesen, Leif, additional, and Lassen, Jens Flensted, additional

Published
2012
Full Text
View/download PDF

11. TCT-297 Stent edge dissections detected by Optical Coherence Tomography, incidence, predictors and 12-month outcome

Author

Christensen, Rasmus, primary, Holm, Niels, additional, Ørhøj, Trine, additional, Maeng, Michael, additional, Krusell, Lars, additional, Terkelsen, Christian, additional, Dijkstra, Jouke, additional, Kaltoft, Anne, additional, Kristensen, Steen, additional, Bøtker, Hans Erik, additional, Thuesen, Leif, additional, Lassen, Jens Flensted, additional, and Christiansen, Evald Høj, additional

Published
2012
Full Text
View/download PDF

12. TCT-283 Intimal Hyperplasia and Vascular Remodeling after Everolimus-eluting and Sirolimus-eluting Stent Implantation in Diabetic Patients. The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) IV Intravascular Ultrasound Trial

Author

Antonsen, Lisbeth, primary, Jensen, Lisette Okkels, additional, Maeng, Michael, additional, Thayssen, Per, additional, Christiansen, Evald Høj, additional, Hansen, Knud Nørregaard, additional, Kaltoft, Anne, additional, Hansen, Henrik Steen, additional, Thuesen, Leif, additional, and Lassen, Jens Flensted, additional

Published
2012
Full Text
View/download PDF

13. 2-Year Patient-Related Versus Stent-Related Outcomes

Author

Jensen, Lisette Okkels, primary, Thayssen, Per, additional, Christiansen, Evald Høj, additional, Tilsted, Hans Henrik, additional, Maeng, Michael, additional, Hansen, Knud Nørregaard, additional, Kaltoft, Anne, additional, Hansen, Henrik Steen, additional, Bøtker, Hans Erik, additional, Krusell, Lars Romer, additional, Ravkilde, Jan, additional, Madsen, Morten, additional, Thuesen, Leif, additional, and Lassen, Jens Flensted, additional

Published
2012
Full Text
View/download PDF

14. Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction

Author

Kaltoft, Anne, primary, Kelbæk, Henning, additional, Thuesen, Leif, additional, Lassen, Jens Flensted, additional, Clemmensen, Peter, additional, Kløvgaard, Lene, additional, Engstrøm, Thomas, additional, Bøtker, Hans E., additional, Saunamäki, Kari, additional, Krusell, Lars R., additional, Jørgensen, Erik, additional, Tilsted, Hans-Henrik, additional, Christiansen, Evald H., additional, Ravkilde, Jan, additional, Køber, Lars, additional, Kofoed, Klaus F., additional, Terkelsen, Christian J., additional, and Helqvist, Steffen, additional

Published
2010
Full Text
View/download PDF

15. Reply

Author

Kaltoft, Anne, primary, Kelbæk, Henning, additional, Kløvgaard, Lene, additional, Terkelsen, Christian Juhl, additional, Clemmensen, Peter, additional, Helqvist, Steffen, additional, Lassen, Jens Flensted, additional, and Thuesen, Leif, additional

Published
2010
Full Text
View/download PDF

17. 2-Year Clinical Outcomes After Implantation of Sirolimus-Eluting, Paclitaxel-Eluting, and Bare-Metal Coronary Stents Results From the WDHR (Western Denmark Heart Registry)

Author

Kaltoft, Anne, Jensen, Lisette Okkels, Maeng, Michael, Tilsted, Hans Henrik, Thayssen, Per, Bøttcher, Morten, Lassen, Jens Flensted, Krusell, Lars Romer, Rasmussen, Klaus, Hansen, Knud Nørregaard, Pedersen, Lars, Johnsen, Søren Paaske, Sørensen, Henrik Toft, and Thuesen, Leif

Subjects
Male, Sirolimus, stent thrombosis, Paclitaxel, Myocardial Infarction, drug-eluting stents, Coronary Disease, Drug-Eluting Stents, Thrombosis, Middle Aged, Cypher, Humans, Female, Stents, Angioplasty, Transluminal, Percutaneous Coronary, Taxus, Immunosuppressive Agents, Aged
Abstract

Udgivelsesdato: 2009-Feb-24 OBJECTIVES: This registry study assessed the safety and efficacy of the 2 types of drug-eluting stents (DES), sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES), compared with bare-metal stents (BMS). BACKGROUND: Drug-eluting stents may increase the risk of stent thrombosis (ST), myocardial infarction (MI), and death. METHODS: A total of 12,395 consecutive patients with coronary intervention and stent implantation recorded in the Western Denmark Heart Registry from January 2002 through June 2005 were followed up for 2 years. Data on death and MI were ascertained from national medical databases. We used Cox regression analysis to control for confounding. RESULTS: The 2-year incidence of definite ST was 0.64% in BMS patients, 0.79% in DES patients (adjusted relative risk [RR]: 1.09; 95% confidence interval [CI]: 0.72 to 1.65), 0.50% in SES patients (adjusted RR: 0.63, 95% CI: 0.35 to 1.15), and 1.30% in PES patients (adjusted RR: 1.82, 95% CI: 1.13 to 2.94). The incidence of MI was 3.8% in BMS-treated patients, 4.5% in DES-treated patients (adjusted RR: 1.24, 95% CI: 1.02 to 1.51), 4.1% in SES-treated patients (adjusted RR: 1.15, 95% CI: 0.91 to 1.47), and 5.3% in PES-treated patients (adjusted RR: 1.38, 95% CI: 1.06 to 1.81). Whereas overall 2-year adjusted mortality was similar in the BMS and the 2 DES stent groups, 12- to 24-month mortality was higher in patients treated with PES (RR 1.46, 95% CI: 1.02 to 2.09). Target lesion revascularization was reduced in both DES groups. CONCLUSIONS: During 2 years of follow-up, patients treated with PES had an increased risk of ST and MI compared with those treated with BMS and SES. Mortality after 12 months was also increased in PES patients.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results